May 19 is #WorldIBDDay, and we’re raising awareness for the millions of people living with inflammatory bowel disease (IBD). Not only does IBD have severe physical impacts, but the disease can also be extremely isolating when those around you don’t understand the severity of your symptoms or how to provide support. Spyre is committed to researching and developing treatment options to improve the experience for all IBD patients. Hear from our experts Joshua R Friedman and Deanna Nguyen to learn more about IBD and what is needed in the treatment landscape. #IBDAwareness #IBD
Spyre Therapeutics’ Post
More Relevant Posts
-
We're #hiring a new Director, Medical Writing in United States. Apply today or share this post with your network.
-
We're #hiring a new Executive Director, Clinical Operations in United States. Apply today or share this post with your network.
-
We are thrilled to share that Spyre is officially certified as a Great Place to Work! This recognition underscores the dedication the Spyre team delivers to build a positive work environment where our employees feel supported every day. At Spyre, one of our core values is an Ownership Mindset, which means we hold ourselves to the highest standard of performance, quality, and integrity as we work through challenges and ambiguity. Thank you to each and every team member for your daily passion and commitment to making Spyre a great place to work! #GreatPlaceToWork #GPTWCertified #OwnershipMindset
-
-
This week marks two significant milestones for Spyre as we celebrate our one-year anniversary and announce the initiation of our first clinical trial evaluating SPY001, an investigational half-life extended anti-α4β7 monoclonal antibody, in healthy volunteers. We are proud of the hard work and dedication that were required to reach this stage and excited about our future with two additional programs expected to enter clinical studies in the next year. Together, we hope these investigational therapies will lead to a meaningful step forward in the treatment of IBD. Learn more: https://lnkd.in/gi-ebw4A #IBD
-
This week, Spyre will attend the 2024 Jefferies Global Healthcare Conference, where our CEO Cameron Turtle will participate in a fireside chat and our team will host investor meetings regarding our investigational next-generation treatment options for patients with inflammatory bowel disease. To learn more about our approach and watch the live webcast, head to ir.spyre.com. #JefferiesHealthcare #IBD
-
-
We are excited to introduce our first #InSpyred employee spotlight, where we recognize employees who inspire us every day. Olivia Ballew, PhD, joined Spyre in November as a Senior Scientist on our non-clinical R&D team. Growing up, Olivia was always interested in science, but it was her genetics class in college that allowed her to dive into the research that really piqued her interest and solidified her passion for the work that she does. When she isn’t working, Olivia is a competitive marathon runner and spends her free time training for upcoming races.
-
Today, we welcome Sandra Milligan, M.D., J.D., to Spyre’s Board of Directors! Dr. Milligan has led a remarkable career with her deep understanding of clinical development and regulatory paths, including in IBD. We are confident Dr. Milligan’s expertise and commitment to patients will help us drive forward our portfolio. Please join us in welcoming Dr. Milligan to the Board! Read the full news here: https://bit.ly/4dJjP8M #IBD #BioTech
-
-
Today, we announced our first quarter financial results for 2024. We are thrilled to be on the cusp of entering clinical studies with our lead programs to research their potential as novel treatment options for those living with IBD. See our latest news release for additional details: https://bit.ly/3UCHVtn Stay tuned as we look forward to an exciting year ahead! #antibody #TL1A #α4β7 #IBD
-
